Gossamer Bio (NASDAQ:GOSS) Stock Price Up 5.1% – Still a Buy?

by · The Cerbat Gem

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) shot up 5.1% during mid-day trading on Monday . The stock traded as high as $3.75 and last traded at $3.7850. 1,433,361 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 2,484,768 shares. The stock had previously closed at $3.60.

Analysts Set New Price Targets

Several brokerages have commented on GOSS. Wall Street Zen upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a report on Thursday, September 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Check Out Our Latest Analysis on GOSS

Gossamer Bio Price Performance

The firm has a market capitalization of $866.82 million, a PE ratio of -5.43 and a beta of 1.92. The company has a 50-day moving average price of $2.75 and a 200 day moving average price of $2.25.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The firm had revenue of $13.29 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, research analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Institutional Trading of Gossamer Bio

A number of large investors have recently made changes to their positions in GOSS. Acadian Asset Management LLC raised its holdings in Gossamer Bio by 24.6% in the 1st quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company’s stock worth $6,991,000 after purchasing an additional 1,253,353 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock worth $1,034,000 after purchasing an additional 825,047 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Gossamer Bio during the first quarter worth approximately $387,000. ProShare Advisors LLC acquired a new position in Gossamer Bio in the 2nd quarter valued at $48,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in Gossamer Bio during the 2nd quarter worth $53,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Further Reading